BioNTech Maintains Buy Rating Despite Analyst Target Price Reductions

H.C. Wainwright maintains a Buy on BioNTech after positive lung cancer trial data, though price targets are cut amid revenue transition and leadership changes.

Investment firm H.C. Wainwright has reaffirmed its Buy recommendation for BioNTech SE, even as it lowered its price target for the biotech company's shares from $140 to $130. This adjustment follows the recent presentation of Phase 2 clinical trial data for the antibody candidate pumitamig at the European Lung Cancer Congress (ELCC) in Copenhagen.

Clinical Data Drives Cautious Optimism

The focal point at the ELCC was pumitamig, an asset co-developed by BioNTech and Bristol-Myers Squibb. In a Phase 2 trial involving 50 patients with advanced small cell lung cancer, the combination of pumitamig and chemotherapy demonstrated a confirmed overall response rate of 82%. The median overall survival for participants was reported at 16.85 months.

Analysts at H.C. Wainwright interpret these results as a risk-mitigating signal for two ongoing pivotal Phase 3 studies: ROSETTA Lung-01 and ROSETTA Lung-02. These trials are designed to test pumitamig against established checkpoint inhibitors, namely Tecentriq and Keytruda. Separately, data from the PRESERVE-003 study for another candidate, gotistobart, showed a 54% reduction in the risk of death compared to chemotherapy alone.

A Trend of Revised Estimates

The move by H.C. Wainwright is part of a broader trend among market observers. Since BioNTech's quarterly report in March, several other firms have also revised their projections downward while maintaining positive ratings:

• Jefferies: Reduced target to $138 from $151; maintains Buy.
• Clear Street: Lowered target to $167 from $181; maintains Buy, noting the stock trades near its cash value.
• Truist Securities: Confirmed a $155 target and Buy rating.
• BMO Capital: Cut its target to $128 from $143. This revision was cited as a reaction to the announced departure of CEO U?ur ?ahin and CMO Özlem Türeci, who plan to launch a new mRNA-focused venture.

Financial Resilience Meets Revenue Headwinds

BioNTech's balance sheet remains a key strength. The company is projected to hold approximately €17.2 billion in cash and cash equivalents by the end of 2025. This substantial financial reserve provides significant runway to fund its extensive clinical pipeline, which includes 16 active trials in lung cancer, four of which are pivotal Phase 3 programs.

However, the transition away from COVID-19 vaccine revenue presents ongoing challenges. Fourth-quarter sales came in at €907 million, surpassing expectations of €759 million but marking a year-over-year decline of roughly 24%. For the full 2026 fiscal year, management anticipates revenues of about €2.15 billion, which would represent a further decrease of approximately 7%. Commercial oncology products have not yet offset the drop in pandemic-related vaccine income.

The equity has traded significantly below its key moving averages recently, shedding around 16% of its value over the past month. The substantial gap between the average analyst price target and the current market price underscores the high expectations placed on the company's oncology pipeline. The pressure to deliver will intensify as more Phase 3 data readouts approach, with several key milestones expected in 2026.